A population-based survey of eczema prevalence in the United States

Jon M. Hanifin, Michael L. Reed, Lynn A. Drake, John Koo, Mark G. Lebwohl, Donald Y M Leung, Robert O. McAlister, David M. Pariser, Scott T. Weiss

Research output: Contribution to journalArticle

  • 166 Citations

Abstract

Background: Eczema and atopic dermatitis (AD) are recognized as major health problems worldwide. Prevalence estimates are as high as one-third of the population, depending on the country studied, the age range of the subjects, and the diagnostic criteria used. National estimates of prevalence for the US population are lacking. Objective: To examine the public health problem posed by eczema, AD, and eczematous conditions in the United States by analyzing disease and symptom prevalence, estimating the number of undiagnosed cases, and assessing comorbidities. Methods: A self-administered questionnaire was sent to a sample of households (N = 60,000) representative of the US population. A designated member responded with information on symptoms, diagnoses, and impact for affected household members; 42,249 households (70%) responded, representing 116,202 individuals. Empirical eczema was defined by itching/scratching and red/inflamed rash or excessive dryness/scaling. Empirical AD was defined by itching/scratching and red/inflamed rash, excessive dryness/scaling, skinfold location, early onset, symptoms lasting ≥ 14 days, or a physician diagnosis of asthma or of allergic rhinitis or hay fever. Results: Of the population studied, 17.1% reported at least one of four eczematous symptoms; empirically defined eczema was found in 10.7%, and empirically defined AD was found in 6%. Prevalence decreased with increasing income. Approximately two-thirds of individuals with an empirical diagnosis of eczema or AD had moderate to severe symptoms, one-third had sleep disturbances, and one-quarter had chronic unremitting symptoms. Just over one-third (37.1%) of those with symptoms reported a physician diagnosis. Peak onset for empirical AD occurred in the group of subjects aged ≤ 5 years. For empirical eczema, peak onset occurred in the group aged 18 to 29 years, and comorbid asthma and hay fever/allergic rhinitis were more prevalent. Conclusions: A substantial proportion of the US population has symptoms of eczema or eczematous conditions; 31.6 million met the empirical symptom criteria for eczema, and 17.8 million met the empirical criteria for AD. Most cases are not diagnosed by a physician, which indicates that these conditions are undertreated and/or managed with nonprescription remedies.

LanguageEnglish (US)
Pages82-91
Number of pages10
JournalDermatitis
Volume18
Issue number2
DOIs
StatePublished - Jun 2007

Fingerprint

Eczema
Atopic Dermatitis
Population
Seasonal Allergic Rhinitis
Pruritus
Exanthema
Physicians
Asthma
Surveys and Questionnaires
Comorbidity
Sleep
Public Health

ASJC Scopus subject areas

  • Dermatology

Cite this

Hanifin, J. M., Reed, M. L., Drake, L. A., Koo, J., Lebwohl, M. G., Leung, D. Y. M., ... Weiss, S. T. (2007). A population-based survey of eczema prevalence in the United States. Dermatitis, 18(2), 82-91. DOI: 10.2310/6620.2007.06034

A population-based survey of eczema prevalence in the United States. / Hanifin, Jon M.; Reed, Michael L.; Drake, Lynn A.; Koo, John; Lebwohl, Mark G.; Leung, Donald Y M; McAlister, Robert O.; Pariser, David M.; Weiss, Scott T.

In: Dermatitis, Vol. 18, No. 2, 06.2007, p. 82-91.

Research output: Contribution to journalArticle

Hanifin, JM, Reed, ML, Drake, LA, Koo, J, Lebwohl, MG, Leung, DYM, McAlister, RO, Pariser, DM & Weiss, ST 2007, 'A population-based survey of eczema prevalence in the United States' Dermatitis, vol. 18, no. 2, pp. 82-91. DOI: 10.2310/6620.2007.06034
Hanifin JM, Reed ML, Drake LA, Koo J, Lebwohl MG, Leung DYM et al. A population-based survey of eczema prevalence in the United States. Dermatitis. 2007 Jun;18(2):82-91. Available from, DOI: 10.2310/6620.2007.06034
Hanifin, Jon M. ; Reed, Michael L. ; Drake, Lynn A. ; Koo, John ; Lebwohl, Mark G. ; Leung, Donald Y M ; McAlister, Robert O. ; Pariser, David M. ; Weiss, Scott T./ A population-based survey of eczema prevalence in the United States. In: Dermatitis. 2007 ; Vol. 18, No. 2. pp. 82-91
@article{6f2783918c43416c86226c5f22e3c18b,
title = "A population-based survey of eczema prevalence in the United States",
abstract = "Background: Eczema and atopic dermatitis (AD) are recognized as major health problems worldwide. Prevalence estimates are as high as one-third of the population, depending on the country studied, the age range of the subjects, and the diagnostic criteria used. National estimates of prevalence for the US population are lacking. Objective: To examine the public health problem posed by eczema, AD, and eczematous conditions in the United States by analyzing disease and symptom prevalence, estimating the number of undiagnosed cases, and assessing comorbidities. Methods: A self-administered questionnaire was sent to a sample of households (N = 60,000) representative of the US population. A designated member responded with information on symptoms, diagnoses, and impact for affected household members; 42,249 households (70{\%}) responded, representing 116,202 individuals. Empirical eczema was defined by itching/scratching and red/inflamed rash or excessive dryness/scaling. Empirical AD was defined by itching/scratching and red/inflamed rash, excessive dryness/scaling, skinfold location, early onset, symptoms lasting ≥ 14 days, or a physician diagnosis of asthma or of allergic rhinitis or hay fever. Results: Of the population studied, 17.1{\%} reported at least one of four eczematous symptoms; empirically defined eczema was found in 10.7{\%}, and empirically defined AD was found in 6{\%}. Prevalence decreased with increasing income. Approximately two-thirds of individuals with an empirical diagnosis of eczema or AD had moderate to severe symptoms, one-third had sleep disturbances, and one-quarter had chronic unremitting symptoms. Just over one-third (37.1{\%}) of those with symptoms reported a physician diagnosis. Peak onset for empirical AD occurred in the group of subjects aged ≤ 5 years. For empirical eczema, peak onset occurred in the group aged 18 to 29 years, and comorbid asthma and hay fever/allergic rhinitis were more prevalent. Conclusions: A substantial proportion of the US population has symptoms of eczema or eczematous conditions; 31.6 million met the empirical symptom criteria for eczema, and 17.8 million met the empirical criteria for AD. Most cases are not diagnosed by a physician, which indicates that these conditions are undertreated and/or managed with nonprescription remedies.",
author = "Hanifin, {Jon M.} and Reed, {Michael L.} and Drake, {Lynn A.} and John Koo and Lebwohl, {Mark G.} and Leung, {Donald Y M} and McAlister, {Robert O.} and Pariser, {David M.} and Weiss, {Scott T.}",
year = "2007",
month = "6",
doi = "10.2310/6620.2007.06034",
language = "English (US)",
volume = "18",
pages = "82--91",
journal = "Dermatitis : contact, atopic, occupational, drug",
issn = "1710-3568",
publisher = "Decker Publishing",
number = "2",

}

TY - JOUR

T1 - A population-based survey of eczema prevalence in the United States

AU - Hanifin,Jon M.

AU - Reed,Michael L.

AU - Drake,Lynn A.

AU - Koo,John

AU - Lebwohl,Mark G.

AU - Leung,Donald Y M

AU - McAlister,Robert O.

AU - Pariser,David M.

AU - Weiss,Scott T.

PY - 2007/6

Y1 - 2007/6

N2 - Background: Eczema and atopic dermatitis (AD) are recognized as major health problems worldwide. Prevalence estimates are as high as one-third of the population, depending on the country studied, the age range of the subjects, and the diagnostic criteria used. National estimates of prevalence for the US population are lacking. Objective: To examine the public health problem posed by eczema, AD, and eczematous conditions in the United States by analyzing disease and symptom prevalence, estimating the number of undiagnosed cases, and assessing comorbidities. Methods: A self-administered questionnaire was sent to a sample of households (N = 60,000) representative of the US population. A designated member responded with information on symptoms, diagnoses, and impact for affected household members; 42,249 households (70%) responded, representing 116,202 individuals. Empirical eczema was defined by itching/scratching and red/inflamed rash or excessive dryness/scaling. Empirical AD was defined by itching/scratching and red/inflamed rash, excessive dryness/scaling, skinfold location, early onset, symptoms lasting ≥ 14 days, or a physician diagnosis of asthma or of allergic rhinitis or hay fever. Results: Of the population studied, 17.1% reported at least one of four eczematous symptoms; empirically defined eczema was found in 10.7%, and empirically defined AD was found in 6%. Prevalence decreased with increasing income. Approximately two-thirds of individuals with an empirical diagnosis of eczema or AD had moderate to severe symptoms, one-third had sleep disturbances, and one-quarter had chronic unremitting symptoms. Just over one-third (37.1%) of those with symptoms reported a physician diagnosis. Peak onset for empirical AD occurred in the group of subjects aged ≤ 5 years. For empirical eczema, peak onset occurred in the group aged 18 to 29 years, and comorbid asthma and hay fever/allergic rhinitis were more prevalent. Conclusions: A substantial proportion of the US population has symptoms of eczema or eczematous conditions; 31.6 million met the empirical symptom criteria for eczema, and 17.8 million met the empirical criteria for AD. Most cases are not diagnosed by a physician, which indicates that these conditions are undertreated and/or managed with nonprescription remedies.

AB - Background: Eczema and atopic dermatitis (AD) are recognized as major health problems worldwide. Prevalence estimates are as high as one-third of the population, depending on the country studied, the age range of the subjects, and the diagnostic criteria used. National estimates of prevalence for the US population are lacking. Objective: To examine the public health problem posed by eczema, AD, and eczematous conditions in the United States by analyzing disease and symptom prevalence, estimating the number of undiagnosed cases, and assessing comorbidities. Methods: A self-administered questionnaire was sent to a sample of households (N = 60,000) representative of the US population. A designated member responded with information on symptoms, diagnoses, and impact for affected household members; 42,249 households (70%) responded, representing 116,202 individuals. Empirical eczema was defined by itching/scratching and red/inflamed rash or excessive dryness/scaling. Empirical AD was defined by itching/scratching and red/inflamed rash, excessive dryness/scaling, skinfold location, early onset, symptoms lasting ≥ 14 days, or a physician diagnosis of asthma or of allergic rhinitis or hay fever. Results: Of the population studied, 17.1% reported at least one of four eczematous symptoms; empirically defined eczema was found in 10.7%, and empirically defined AD was found in 6%. Prevalence decreased with increasing income. Approximately two-thirds of individuals with an empirical diagnosis of eczema or AD had moderate to severe symptoms, one-third had sleep disturbances, and one-quarter had chronic unremitting symptoms. Just over one-third (37.1%) of those with symptoms reported a physician diagnosis. Peak onset for empirical AD occurred in the group of subjects aged ≤ 5 years. For empirical eczema, peak onset occurred in the group aged 18 to 29 years, and comorbid asthma and hay fever/allergic rhinitis were more prevalent. Conclusions: A substantial proportion of the US population has symptoms of eczema or eczematous conditions; 31.6 million met the empirical symptom criteria for eczema, and 17.8 million met the empirical criteria for AD. Most cases are not diagnosed by a physician, which indicates that these conditions are undertreated and/or managed with nonprescription remedies.

UR - http://www.scopus.com/inward/record.url?scp=34547152817&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34547152817&partnerID=8YFLogxK

U2 - 10.2310/6620.2007.06034

DO - 10.2310/6620.2007.06034

M3 - Article

VL - 18

SP - 82

EP - 91

JO - Dermatitis : contact, atopic, occupational, drug

T2 - Dermatitis : contact, atopic, occupational, drug

JF - Dermatitis : contact, atopic, occupational, drug

SN - 1710-3568

IS - 2

ER -